What we're reading, January 20, 2016: UnitedHealth losses on Obamacare health plans steepen; more "skin in the game" doesn't necessarily result in savvier shoppers; and despite recommendations few high school students are tested for HIV.
Last year, UnitedHealth made the surprising announcement that it was considering pulling back from the Affordable Care Act (ACA) health insurance exchanges in 2017 due to steep losses. Now, the damage has worsened. The company has projected deeper losses due to growing enrollment, reported The Wall Street Journal. UnitedHealth has made efforts to reduce sign-ups, but regardless, it is expecting losses of more than $500 million on its 2016 ACA plans. The exchange plans represent just a small part of the company’s total business.
Increasing patients’ “skin in the game” does not necessarily lead to savvier consumers. Researchers questioned people about what factors impact their decisions and found even when people have more responsibility for their health costs, they aren’t any more likely to shop around or consider costs, according to Kaiser Health News. Part of the issue, is that it is still difficult for consumers to compare prices when shopping.
Despite recommendations from CDC, the rate of high school students who should have been tested for HIV but haven’t been hasn’t budged over 8 years. Fewer than one-fourth of high school students who have had sex have been tested, because some teens underestimate their risk and their physicians are unaware of the recommendations, reported The Washington Post. CDC recommends yearly HIV testing for high-risk patients, such as those with multiple sex partners—15% of high school students report having at least 4 partners—gay or bisexual boys and men, and injection drug users.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Significant Disease Burden and Management Issues in Chronic Spontaneous Urticaria
April 15th 2025Patients with chronic spontaneous urticaria experienced a long delay in diagnosis, a substantial impact on their quality of life, and often received inadequate treatment, highlighting the need for better management and understanding of the condition.
Read More
Lifestyle Interventions, Statins, Among Keys to Mitigating CVD Risk in MASLD/MASH
April 15th 2025A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like peptide 1 (GLP-1) receptor agonists for liver conditions.
Read More